Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The entity "novel transcript, antisense to SFMBT1" (ENSG00000305550) refers to an uncharacterized or predicted transcript that is transcribed from the DNA strand opposite to the canonical SFMBT1 gene. There is no evidence in the biomedical literature or major gene/protein databases indicating that this antisense RNA is a protein-coding gene, nor that it encodes a therapeutic target such as a receptor, enzyme, or transporter. It is not considered a validated gene, nor is there information on its biological function, disease association, or drug targeting potential. The canonical, protein-coding SFMBT1 gene (ENSG00000163935), by contrast, encodes a chromatin-associated transcriptional corepressor and is unrelated to this antisense transcript.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to SFMBT1.